Ebb_Logomark_TwoColor_Primary_R_PMS.png

A NEW APPROACH TO TREATING INSOMNIA, COMBINING EMERGING SCIENCE, TECHNOLOGY AND SUPPORT

Ebb Therapeutics is revolutionizing sleep therapy with the first FDA-cleared drug-free approach to insomnia. FIVE and Ebb worked together to re-envision the patient journey and identify novel opportunities to improve patient engagement and adherence. As part of their work together, FIVE has conducted patient interviews and journey mapping workshops as well as provided strategic guidance and new service design and implementation support.

Ebb™ Insomnia Therapy is the first and only FDA-cleared device that reduces the time it takes to both fall asleep and enter deeper, more restorative sleep. Invented by an internationally recognized leader in sleep medicine, Eric Nofzinger, MD, Ebb works with the body to gently cool and calm the overactive mind.

Ebb™ Insomnia Therapy is the first and only FDA-cleared device that reduces the time it takes to both fall asleep and enter deeper, more restorative sleep. Invented by an internationally recognized leader in sleep medicine, Eric Nofzinger, MD, Ebb works with the body to gently cool and calm the overactive mind.

THE LINK BETWEEN MIND AND SLEEP

Ebb’s founder, Dr. Nofzinger, discovered through brain imaging studies that when the front of the brain shows a reduction in activity, the person falls into a restorative sleep. But people suffering from insomnia have an increase in front brain activity.

By having a window into the minds of patients seeking sleep, he was able to make a significant discovery that would eventually lead to a revolutionary sleep solution.

Armed with a clearer understanding of what’s happening in the brains of those suffering from insomnia, Dr. Nofzinger began his development of a drug-free solution that reduces brain activity and helps calm the mind by precisely cooling the forehead.

The opportunity to transform the lives of individuals experiencing insomnia has fueled the continuing development of the Ebb Insomnia Therapy.